This Earmarked Scholarship project is aligned with a recently awarded Category 1 research grant. It offers you the opportunity to work with leading researchers and contribute to large projects of national significance.
Supervisor – Associate Professor Luregn Schlapbach, l.schlapbach@uq.edu.au
Sepsis and life-threatening infections are a major cause of childhood morbidity and death in Australia and worldwide.
Timely and appropriate initiation of antimicrobial therapy is a cornerstone of treatment. Current treatment recommendations use standard dosing recommendations across broad patient groups.
More recently, drug dosing software has become available which can enable more personalized drug therapy.
The aim of this project is to conduct prospective research on children with severe infections admitted to intensive care, investigating approaches to optimize drug therapy, including dosing software.
The candidate will perform a literature review, followed by a prospective study with co-supervision from experts in paediatric sepsis and intensive care, and pharmacology.
Preferred educational background
Applications will be judged on a competitive basis taking into account the applicant's previous academic record, publication record, honours and awards, and employment history.
The preferred candidate has a strong background in paediatric pharmacology and pharmacy, and is familiar with current state-of-the-art drug delivery quality procedures.
The candidate should have a strong interest in severe infections in children and is keen to engage in a prospective study.
*The successful candidate must commence by Research Quarter 4, 2021. You should apply at least 3 months prior to the research quarter commencement date. International applicants may need to apply much earlier for visa reasons.